Oramed Pharmaceuticals Inc.

    Jurisdiction
    United States
    LEI
    5299006K52ZIIGQJ6R84
    ISIN
    US68403P2039 (ORMP)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Read full profile

    Fundamentals

    Net revenue
    €1.71M
    Gross margin
    -2.4%
    EBIT
    -€11.66M
    EBIT margin
    -683.7%
    Net income
    -€20.61M
    Net margin
    -1,208.1%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Congress transactions

    Name Transaction date Value
    Brad Knott February 25, 2025 $15.00K–$50.00K

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 143K $304.95K -9.3K Sell

    Earnings Calls

    Add to watchlist

    Notifications